Buy Adepress pills 20 mg, 30 pcs
  • Buy Adepress pills 20 mg, 30 pcs


853 Items
Dosage form
Brand & Manufacturer
Package Size
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology

Adepress - antidepressant. It is a selective serotonin reuptake inhibitor (5-hydroxytryptamine, 5-HT) by brain neurons, which determines its antidepressant effect and effectiveness in the treatment of obsessive-compulsive (OCD) and panic disorder.

Paroxetine has a low affinity for m-cholinergic receptors (has a weak anticholinergic effect), α1, α2 and β-adrenergic receptors, as well as to dopamine (D2), 5HT1-like, 5HT2-like and histamine H1 receptors. Paroxetine does not violate the psychomotor functions and does not potentiate the inhibitory effect on them of ethanol.

According to the study of behavior and EEG in paroxetine, weak activating properties are detected when it is prescribed in doses higher than those necessary for inhibiting serotonin uptake. In healthy volunteers, it does not cause a significant change in the level of blood pressure, heart rate and EEG.


Depression of all types, including reactive, severe endogenous depression and depression, accompanied by anxiety;
Obsessive Compulsive Disorder (OCD);
Panic disorder, incl. with fear of being in a crowd (agoraphobia);
Social anxiety disorder / social phobia;
Generalized anxiety disorder;
Posttraumatic stress disorder.


1 tab. contains paroxetine (in the form of hemihydrate hydrochloride) 20 mg;
excipients: calcium hydrophosphate (calcium phosphate disubstituted), corn starch, sodium carboxymethyl starch (primogel), magnesium stearate

Paroxetine is marketed under different brands and generic names, and comes in different dosage forms:

Brand nameManufacturerCountryDosage form
Adepress Veropharm Russia pills
Plizil Teva Israel pills
Rexetin® Gedeon Richter Hungary pills
Paxil GlaxoSmithKline UK pills

No customer reviews for the moment.

Write your review

Write your review


Dosage and Administration

Adepress should be administered 1 time / day, in the morning, during meals, without chewing, drinking water.

The dose is selected individually during the first 2-3 weeks after the start of therapy and is adjusted if necessary. The effect in most cases develops gradually. The dose should be increased by 10 mg every week to achieve a therapeutic effect. The maximum daily dose should not exceed 60 mg / day.

For renal and / or liver failure, the recommended dose is 20 mg / day.

For elderly patients, the daily dose should not exceed 40 mg.

To prevent relapse, maintenance therapy is necessary. After the disappearance of the symptoms of depression, this course may be 4-6 months, and for obsessive and panic disorders - more than 4-6 months.

Avoid abrupt withdrawal of the drug. In order to prevent the development of withdrawal syndrome, discontinuation of the drug Adepress should be carried out gradually.

Adverse reactions

From the side of the central nervous system and peripheral nervous system:often - drowsiness or insomnia, tremor, asthenia, dizziness, anxiety; sometimes - confusion, hallucinations, extrapyramidal disorders, paresthesias, reduced ability to concentrate; rarely - cramps, mania; very rarely - serotonin syndrome (agitation, hyperreflexia, diarrhea), panic disorders.
From the senses: in some cases - visual impairment, mydriasis.
From the musculoskeletal system: rarely - myasthenia, myoclonia, arthralgia, myalgia.
From the urinary system: frequent urination; rarely - urinary retention.
From the reproductive system:ejaculatory disorders, libido disorders; rarely - hyperprolactinemia / galactorrhea, anorgasmia.
From the digestive system:loss of appetite, nausea, vomiting, dry mouth; sometimes constipation or diarrhea; in some cases - hepatitis.
Since the cardiovascular system: orthostatic hypotension.
Allergic reactions:rarely - rash, urticaria, ecchimatosis, pruritus, angioedema.
Other:increased sweating; in isolated cases - hyponatremia, impaired secretion of antidiuretic hormone.


Simultaneous administration of MAO inhibitors and a period of 14 days after their withdrawal;
Unstable epilepsy;
Pregnancy and lactation (breastfeeding);
Hypersensitivity to the drug.

Carefully: in liver failure, renal failure, angle-closure glaucoma, prostatic hyperplasia, mania, cardiac pathology, epilepsy, convulsive states, simultaneous administration of electropulse therapy, simultaneous administration of drugs that increase the risk of bleeding, the risk factors for increased bleeding and diseases that increase the risk of bleeding, as well as elderly patients.

Special instructions

In order to avoid the development of neuroleptic malignant syndrome, Adepress should be prescribed with caution to patients taking neuroleptics.

In elderly patients, while receiving Adepress, hyponatremia is possible.

In some cases, it is necessary to adjust the dose of simultaneously used insulin and / or oral hypoglycemic drugs.

With the development of seizures, treatment with Adepress is stopped.

At the first signs of mania, the drug should be withdrawn.

During the first few weeks of treatment with Adepress, the patient’s condition should be carefully monitored for possible suicidal attempts.

During therapy Adepressom should refrain from taking alcohol in connection with the strengthening of its toxic effect.

Influence on ability to drive motor transport and control mechanisms
Despite the fact that paroxetine does not impair cognitive and psychomotor functions, patients should refrain or exercise extreme caution when driving and while engaging in other potentially dangerous activities that require increased concentration and psychomotor speed.

  • Brand name: Adepress
  • Active ingredient: Paroxetine
  • Dosage form: Coated pills
  • Manufacturer: Veropharm
  • Country of Origin: Russia

Studies and clinical trials of Paroxetine (Click to expand)

  1. Paracetamol/pheniramine/phenylephrine
  2. Inhibition of hippocampal 5-HT synthesis by fluoxetine and paroxetine: Evidence for the involvement of both 5-HT1A and 5-HT1B/D autoreceptors
  3. The Effect of Paroxetine and Dothiepin on Subjective Sleep in Depressed Patients
  4. Effectiveness of Fluvoxamine and Paroxetine in Major Depressives with Psychotic Features
  5. Withdrawal symptoms from paroxetine
  6. A double-blind comparison of the efficacy and safety of paroxetine and imipramine in the treatment of depression with dementia
  7. Letter to the Editor: Serotonin syndrome following the administration of tramadol with paroxetine
  8. A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies
  9. Accelerating response in geriatric depression: A pilot study combining sleep deprivation and paroxetine
  10. Effects of nortriptyline and paroxetine on QT variability in patients with panic disorder
  11. Therapeutic advances: Paroxetine for the treatment of social anxiety disorder
  12. Effect of antenatal exposure to paroxetine (Paxil) on growth and physical maturation of mice offspring
  13. A Formal Synthesis of (−)-Paroxetine by Enantioselective Ring Enlargement of a Trisubstituted Prolinol
  14. Relationship between clinical effects, serum drug concentration, and concurrent drug interactions in depressed patients treated with citalopram, fluoxetine, clomipramine, paroxetine or venlafaxine
  15. Paroxetine versus nortriptyline in the continuation and maintenance treatment of depression in the elderly
  16. Tolerability of paroxetine in Parkinson's disease: A prospective study
  17. The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression
  18. Paroxetine retards disease onset and progression in Huntingtin mutant mice
  19. Organocatalytic Conjugate Addition of Malonates to α,β-Unsaturated Aldehydes: Asymmetric Formal Synthesis of (−)-Paroxetine, Chiral Lactams, and Lactones
  20. Organocatalytic Conjugate Addition of Malonates to α,β-Unsaturated Aldehydes: Asymmetric Formal Synthesis of (−)-Paroxetine, Chiral Lactams, and Lactones
  21. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: A meta-analysis of epidemiological studies
  22. First-trimester use of paroxetine and congenital heart defects: A population-based case-control study
  23. Paroxetine exposure during pregnancy and the risk of cardiac malformations: What is the evidence?
  24. Paroxetine exposure during pregnancy and cardiac malformations
  25. First trimester exposure to paroxetine and prevalence of cardiac defects: Meta-analysis of the literature: Unfortunately incomplete
  26. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage

Customers who bought this product also bought:

8 other products in the same category: